Cipla: Nishant Saxena
Nishant Saxena was the Chief Financial Officer of Cipla South Africa from May 2014 until September 2017. He is now the Global Chief Strategy Officer.
Nishant Saxena came from India to join the Cipla Sub-Saharan Africa branch. He holds both an MBA and an engineering degree from the Indian Institute of Management and began his career with Proctor & Gamble, where he gained global experience working in Japan, Philippines, Singapore and South Africa. He is an award-winning social entrepreneur and has lectured at leading universities on a part-time basis. He joined Cipla in 2013 as Chief Financial Officer and in 2017 he moved on to become the Global Chief Strategy Officer of Cipla.
Nishant was awarded the Young CFO of the Year Award and the High Performance Team Award at the 2017 CFO Awards.
2017 – Present Global Chief Strategy Officer, Cipla
2016 – 2017 Chief Financial Officer, Director of Business Development M&A, Cipla South Africa
2014 – 2016 Chief Financial and Administrative Officer, Cipla South Africa
2013 – 2014 Chief Financial Officer, Cipla India
2007 – 2013 Founder, CEO, Elements Akademia
2005 – 2007 Regional Finance Manager, Procter & Gamble, Asia
2004 – 2005 Deputy Chief Financial Officer, Procter & Gamble, India Operations
2002 – 2004 Section Manager, Procter & Gamble
2000 – 2002 Analyst, Procter & Gamble
2012 – 2012 Advanced Course in Entrepreneurship, The University of Chicago Booth School of Business
1998 – 2000 MBA, Finance and Strategy, Indian Institute of Management
1994 – 1998 BE, Production Engineering, National Institute of Technology Trichy
1981 – 1994 Matric, St Joseph’s College, Allahabad
About Cipla: Cipla is a global pharmaceutical company which uses cutting-edge technology and innovation to meet the everyday needs of all patients. Over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Its portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.
While delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.